ONFO vs ITRM vs PRAX vs HIMS vs ACAD

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 8x trailing P/E (55. 6x forward), making it the more compelling value choice. Analysts rate Praxis Precision Medicines, Inc. (PRAX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACADIA Pharmaceuticals Inc.

(ACAD) is the cheapest at 9. 8x versus Hims & Hers Health, Inc. at 55. 4x. On forward P/E, ACADIA Pharmaceuticals Inc. is actually cheaper at 55. 6x.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +173. 9%, compared to -99. 8% for Iterum Therapeutics plc (ITRM). Over 10 years, the gap is even starker: HIMS returned +188. 5% versus ITRM's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ACADIA Pharmaceuticals Inc.

(ACAD) is the lower-risk stock at 1. 11β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately 122% more volatile than ACAD relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Onfolio Holdings, Inc. grew EPS 75. 0% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus -69. 1% for Iterum Therapeutics plc — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -52. 0% for ITRM. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ACADIA Pharmaceuticals Inc.

(ACAD) trades at 55. 6x forward P/E versus 58. 3x for Hims & Hers Health, Inc. — 2. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRAX: 66. 3% to $548. 80.

In this comparison, ONFO (5.

5% yield) pays a dividend. ITRM, PRAX, HIMS, ACAD do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Onfolio Holdings, Inc.

(ONFO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (5. 5% yield). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 48 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ONFO: -52. 5%, HIMS: +188. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ONFO (Communication Services) and ITRM (Healthcare) and PRAX (Healthcare) and HIMS (Healthcare) and ACAD (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ONFO is a small-cap high-growth stock; ITRM is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; ACAD is a small-cap deep-value stock. ONFO pays a dividend while ITRM, PRAX, HIMS, ACAD do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.